Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase

BE0023607ProteinHumansURAD

Catalyzes the stereoselective decarboxylation of 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline (OHCU) to (S)-allantoin, a step in the uric acid degradation pathway following urate oxidation (By similarity). It is acted on by 1 drug in DrugBank.

Gene name
URAD
UniProtKB entry
A6NGE7Swiss-Prot
Cellular location
Peroxisome
Residues / weight
173 residues · 19,130 Da
Also known as
4.1.1.97 · OHCU decarboxylase · Parahox neighbor · PRHOXNB · Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase

Resolves to

Protein
UniProtA6NGE7UniProt nameURAD_HUMAN
Gene
HGNCHGNC:17785NCBI Gene646625GeneCardsURAD
Pharmacology
KEGGhsa:646625
Drugs

What you can answer from here — as of September 03, 2024

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
4GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which approved drugs act on Putative 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In